Indication
Chronic heart failure following myocardial infarction
Chronic heart failure following myocardial infarction is a progressive cardiovascular syndrome characterized by the persistent inability of the heart to maintain adequate systemic perfusion. Read more about Chronic heart failure following myocardial infarction
35 drugs 32 manufacturers
Drugs that treat it
Common Chronic heart failure following myocardial infarction therapies.
RAMIPRIL
EPLERENONE
EPLERENONE
RAMIPRIL
RAMIPRIL
RAMIPRIL
EPLERENONE
RAMIPRIL
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonChronic heart failure following myocardial infarction is a progressive cardiovascular syndrome characterized by the persistent inability of the heart to maintain adequate systemic perfusion.
Affecting patients with prior ischemic myocardial injury, it develops primarily due to irreversible cardiomyocyte loss, infarct scar formation, and adverse ventricular remodeling that precipitates left ventricular systolic or combined dysfunction.
Pathophysiologically, ongoing neurohormonal activation—including the renin-angiotensin-aldosterone and sympathetic nervous systems—drives progressive ventricular dilation, chamber wall thinning, and myocardial fibrosis.
Clinically, affected individuals experience chronic exertional dyspnea, fatigue, reduced exercise tolerance, and signs of systemic or pulmonary venous congestion.
- news-medical.net
Chronic heart failure following myocardial infarction is a progressive cardiovascular syndrome characterized by the persistent inability of the heart to maintain adequate systemic perfusion
- nih.gov
Affecting patients with prior ischemic myocardial injury, it develops primarily due to irreversible cardiomyocyte loss, infarct scar formation, and adverse ventricular remodeling that precipitates left ventricular systolic or combined dysfunction Clinically, affected individuals experience chronic exertional dyspnea, fatigue, reduced exercise tolerance, and signs of systemic or pulmonary venous congestion
- nih.gov
Affecting patients with prior ischemic myocardial injury, it develops primarily due to irreversible cardiomyocyte loss, infarct scar formation, and adverse ventricular remodeling that precipitates left ventricular systolic or combined dysfunction Pathophysiologically, ongoing neurohormonal activation—including the renin-angiotensin-aldosterone and sympathetic nervous systems—drives progressive ventricular dilation, chamber wall thinning, and myocardial fibrosis
- amegroups.org
Pathophysiologically, ongoing neurohormonal activation—including the renin-angiotensin-aldosterone and sympathetic nervous systems—drives progressive ventricular dilation, chamber wall thinning, and myocardial fibrosis Clinically, affected individuals experience chronic exertional dyspnea, fatigue, reduced exercise tolerance, and signs of systemic or pulmonary venous congestion
Personalize your experience
Follow Chronic heart failure following myocardial infarction and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.